Red cell distribution width and prognosis in myelofibrosis patients treated with ruxolitinib
We evaluated RDW in a single-center series of 61 consecutive patients with primary and secondary MF at diagnosis and during treatment with ruxolitinib (RUX) and examined any possible prognostic impact. Elevated RDW values were present in all but 4 patients at diagnosis with a median RDW of 18.9%. RD...
Gespeichert in:
| Veröffentlicht in: | Annals of hematology 2024-08, Vol.103 (8), p.2787-2795 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2795 |
|---|---|
| container_issue | 8 |
| container_start_page | 2787 |
| container_title | Annals of hematology |
| container_volume | 103 |
| creator | Cattaneo, Daniele Galli, Nicole Bucelli, Cristina Fidanza, Cecilia Anna Bellani, Valentina Artuso, Silvia Bianchi, Paola Consonni, Dario Passamonti, Francesco Iurlo, Alessandra |
| description | We evaluated RDW in a single-center series of 61 consecutive patients with primary and secondary MF at diagnosis and during treatment with ruxolitinib (RUX) and examined any possible prognostic impact. Elevated RDW values were present in all but 4 patients at diagnosis with a median RDW of 18.9%. RDW was higher in subjects with palpable splenomegaly (
p
= 0.02), higher ferritin, as well as among those cases who did not receive any cytoreduction before RUX (
p
= 0.04). Interestingly, higher RDW at diagnosis also correlated with a shorter time from MF diagnosis to RUX start (-4.1 months per one RDW unit;
p
= 0.03). We observed a modest increase ( |
| doi_str_mv | 10.1007/s00277-024-05801-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3085113491</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3085113491</sourcerecordid><originalsourceid>FETCH-LOGICAL-c256t-557c03fe69e9451ca5d7e1f048a58cfb58ca75756c1f7b58550dcfe439abebc83</originalsourceid><addsrcrecordid>eNp9kEtLAzEUhYMotlb_gAsJuHEzejNJ5rEU8QUFQXQnhEwmU1OmmZpkqP33pp2q4MIsEm7ynZN7D0KnBC4JQH7lAdI8TyBlCfACSAJ7aEwYTTcl20djKGmZ8LhG6Mj7OQBJC5YeohEtioyVwMbo7VnXWOm2xbXxwZmqD6azeGXq8I6lrfHSdTPbeeOxsXix1m3XmMptL5YyGG2Dx8FpGaLPykSR6z-71gRjTXWMDhrZen2yOyfo9e725eYhmT7dP95cTxOV8izEDnMFtNFZqUvGiZK8zjVpgBWSF6qp4iZznvNMkSaPFedQq0YzWspKV6qgE3Qx-MZmP3rtg1gYvxlKWt31XlAoOCGUlSSi53_Qedc7G7sbqCxGVEYqHSgVJ_VON2LpzEK6tSAgNtmLIXsRsxfb7AVE0dnOuq8Wuv6RfIcdAToAPj7ZmXa_f_9j-wUPK5Bt</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3085161289</pqid></control><display><type>article</type><title>Red cell distribution width and prognosis in myelofibrosis patients treated with ruxolitinib</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Cattaneo, Daniele ; Galli, Nicole ; Bucelli, Cristina ; Fidanza, Cecilia Anna ; Bellani, Valentina ; Artuso, Silvia ; Bianchi, Paola ; Consonni, Dario ; Passamonti, Francesco ; Iurlo, Alessandra</creator><creatorcontrib>Cattaneo, Daniele ; Galli, Nicole ; Bucelli, Cristina ; Fidanza, Cecilia Anna ; Bellani, Valentina ; Artuso, Silvia ; Bianchi, Paola ; Consonni, Dario ; Passamonti, Francesco ; Iurlo, Alessandra</creatorcontrib><description>We evaluated RDW in a single-center series of 61 consecutive patients with primary and secondary MF at diagnosis and during treatment with ruxolitinib (RUX) and examined any possible prognostic impact. Elevated RDW values were present in all but 4 patients at diagnosis with a median RDW of 18.9%. RDW was higher in subjects with palpable splenomegaly (
p
= 0.02), higher ferritin, as well as among those cases who did not receive any cytoreduction before RUX (
p
= 0.04). Interestingly, higher RDW at diagnosis also correlated with a shorter time from MF diagnosis to RUX start (-4.1 months per one RDW unit;
p
= 0.03). We observed a modest increase (< 1%) in RDW during the first 6 months of RUX treatment. In a multivariable random-intercept model that considered all time points and contained the covariates time and RUX dose, we also observed a clear decrease in RDW with increasing hemoglobin (Hb) during RUX (slope: -0.4% per g/dL of Hb;
p
< 0.001). The median RDW at diagnosis of 18.9% was used as a cut-off to identify two subgroups of patients [Group 1: RDW 19.0-25.7%; Group 2: RDW 13.1-18.7%], showing a difference in mortality [Group 1 vs. 2: crude HR 2.88;
p
= 0.01]. Using continuous RDW at diagnosis, the crude HR was 1.21 per RDW unit (
p
= 0.002). In a Cox model adjusted for gender, age and Hb at diagnosis, the HR was 1.13 per RDW unit (
p
= 0.07). RDW may have prognostic significance at MF diagnosis and during RUX, helping in the rapid detection of patients with poor prognosis.</description><identifier>ISSN: 0939-5555</identifier><identifier>ISSN: 1432-0584</identifier><identifier>EISSN: 1432-0584</identifier><identifier>DOI: 10.1007/s00277-024-05801-0</identifier><identifier>PMID: 38864904</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Automation ; Biopsy ; Bone marrow ; Cytokines ; Erythrocyte Indices ; Female ; Hematology ; Hemoglobin ; Humans ; Male ; Medical prognosis ; Medicine ; Medicine & Public Health ; Middle Aged ; Mortality ; Mutation ; Nitriles - therapeutic use ; Oncology ; Primary Myelofibrosis - blood ; Primary Myelofibrosis - drug therapy ; Primary Myelofibrosis - mortality ; Prognosis ; Pyrazoles - therapeutic use ; Pyrimidines - therapeutic use ; Spleen ; Stem cells</subject><ispartof>Annals of hematology, 2024-08, Vol.103 (8), p.2787-2795</ispartof><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c256t-557c03fe69e9451ca5d7e1f048a58cfb58ca75756c1f7b58550dcfe439abebc83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00277-024-05801-0$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00277-024-05801-0$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38864904$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cattaneo, Daniele</creatorcontrib><creatorcontrib>Galli, Nicole</creatorcontrib><creatorcontrib>Bucelli, Cristina</creatorcontrib><creatorcontrib>Fidanza, Cecilia Anna</creatorcontrib><creatorcontrib>Bellani, Valentina</creatorcontrib><creatorcontrib>Artuso, Silvia</creatorcontrib><creatorcontrib>Bianchi, Paola</creatorcontrib><creatorcontrib>Consonni, Dario</creatorcontrib><creatorcontrib>Passamonti, Francesco</creatorcontrib><creatorcontrib>Iurlo, Alessandra</creatorcontrib><title>Red cell distribution width and prognosis in myelofibrosis patients treated with ruxolitinib</title><title>Annals of hematology</title><addtitle>Ann Hematol</addtitle><addtitle>Ann Hematol</addtitle><description>We evaluated RDW in a single-center series of 61 consecutive patients with primary and secondary MF at diagnosis and during treatment with ruxolitinib (RUX) and examined any possible prognostic impact. Elevated RDW values were present in all but 4 patients at diagnosis with a median RDW of 18.9%. RDW was higher in subjects with palpable splenomegaly (
p
= 0.02), higher ferritin, as well as among those cases who did not receive any cytoreduction before RUX (
p
= 0.04). Interestingly, higher RDW at diagnosis also correlated with a shorter time from MF diagnosis to RUX start (-4.1 months per one RDW unit;
p
= 0.03). We observed a modest increase (< 1%) in RDW during the first 6 months of RUX treatment. In a multivariable random-intercept model that considered all time points and contained the covariates time and RUX dose, we also observed a clear decrease in RDW with increasing hemoglobin (Hb) during RUX (slope: -0.4% per g/dL of Hb;
p
< 0.001). The median RDW at diagnosis of 18.9% was used as a cut-off to identify two subgroups of patients [Group 1: RDW 19.0-25.7%; Group 2: RDW 13.1-18.7%], showing a difference in mortality [Group 1 vs. 2: crude HR 2.88;
p
= 0.01]. Using continuous RDW at diagnosis, the crude HR was 1.21 per RDW unit (
p
= 0.002). In a Cox model adjusted for gender, age and Hb at diagnosis, the HR was 1.13 per RDW unit (
p
= 0.07). RDW may have prognostic significance at MF diagnosis and during RUX, helping in the rapid detection of patients with poor prognosis.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Automation</subject><subject>Biopsy</subject><subject>Bone marrow</subject><subject>Cytokines</subject><subject>Erythrocyte Indices</subject><subject>Female</subject><subject>Hematology</subject><subject>Hemoglobin</subject><subject>Humans</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>Mutation</subject><subject>Nitriles - therapeutic use</subject><subject>Oncology</subject><subject>Primary Myelofibrosis - blood</subject><subject>Primary Myelofibrosis - drug therapy</subject><subject>Primary Myelofibrosis - mortality</subject><subject>Prognosis</subject><subject>Pyrazoles - therapeutic use</subject><subject>Pyrimidines - therapeutic use</subject><subject>Spleen</subject><subject>Stem cells</subject><issn>0939-5555</issn><issn>1432-0584</issn><issn>1432-0584</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kEtLAzEUhYMotlb_gAsJuHEzejNJ5rEU8QUFQXQnhEwmU1OmmZpkqP33pp2q4MIsEm7ynZN7D0KnBC4JQH7lAdI8TyBlCfACSAJ7aEwYTTcl20djKGmZ8LhG6Mj7OQBJC5YeohEtioyVwMbo7VnXWOm2xbXxwZmqD6azeGXq8I6lrfHSdTPbeeOxsXix1m3XmMptL5YyGG2Dx8FpGaLPykSR6z-71gRjTXWMDhrZen2yOyfo9e725eYhmT7dP95cTxOV8izEDnMFtNFZqUvGiZK8zjVpgBWSF6qp4iZznvNMkSaPFedQq0YzWspKV6qgE3Qx-MZmP3rtg1gYvxlKWt31XlAoOCGUlSSi53_Qedc7G7sbqCxGVEYqHSgVJ_VON2LpzEK6tSAgNtmLIXsRsxfb7AVE0dnOuq8Wuv6RfIcdAToAPj7ZmXa_f_9j-wUPK5Bt</recordid><startdate>20240801</startdate><enddate>20240801</enddate><creator>Cattaneo, Daniele</creator><creator>Galli, Nicole</creator><creator>Bucelli, Cristina</creator><creator>Fidanza, Cecilia Anna</creator><creator>Bellani, Valentina</creator><creator>Artuso, Silvia</creator><creator>Bianchi, Paola</creator><creator>Consonni, Dario</creator><creator>Passamonti, Francesco</creator><creator>Iurlo, Alessandra</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20240801</creationdate><title>Red cell distribution width and prognosis in myelofibrosis patients treated with ruxolitinib</title><author>Cattaneo, Daniele ; Galli, Nicole ; Bucelli, Cristina ; Fidanza, Cecilia Anna ; Bellani, Valentina ; Artuso, Silvia ; Bianchi, Paola ; Consonni, Dario ; Passamonti, Francesco ; Iurlo, Alessandra</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c256t-557c03fe69e9451ca5d7e1f048a58cfb58ca75756c1f7b58550dcfe439abebc83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Automation</topic><topic>Biopsy</topic><topic>Bone marrow</topic><topic>Cytokines</topic><topic>Erythrocyte Indices</topic><topic>Female</topic><topic>Hematology</topic><topic>Hemoglobin</topic><topic>Humans</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>Mutation</topic><topic>Nitriles - therapeutic use</topic><topic>Oncology</topic><topic>Primary Myelofibrosis - blood</topic><topic>Primary Myelofibrosis - drug therapy</topic><topic>Primary Myelofibrosis - mortality</topic><topic>Prognosis</topic><topic>Pyrazoles - therapeutic use</topic><topic>Pyrimidines - therapeutic use</topic><topic>Spleen</topic><topic>Stem cells</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cattaneo, Daniele</creatorcontrib><creatorcontrib>Galli, Nicole</creatorcontrib><creatorcontrib>Bucelli, Cristina</creatorcontrib><creatorcontrib>Fidanza, Cecilia Anna</creatorcontrib><creatorcontrib>Bellani, Valentina</creatorcontrib><creatorcontrib>Artuso, Silvia</creatorcontrib><creatorcontrib>Bianchi, Paola</creatorcontrib><creatorcontrib>Consonni, Dario</creatorcontrib><creatorcontrib>Passamonti, Francesco</creatorcontrib><creatorcontrib>Iurlo, Alessandra</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cattaneo, Daniele</au><au>Galli, Nicole</au><au>Bucelli, Cristina</au><au>Fidanza, Cecilia Anna</au><au>Bellani, Valentina</au><au>Artuso, Silvia</au><au>Bianchi, Paola</au><au>Consonni, Dario</au><au>Passamonti, Francesco</au><au>Iurlo, Alessandra</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Red cell distribution width and prognosis in myelofibrosis patients treated with ruxolitinib</atitle><jtitle>Annals of hematology</jtitle><stitle>Ann Hematol</stitle><addtitle>Ann Hematol</addtitle><date>2024-08-01</date><risdate>2024</risdate><volume>103</volume><issue>8</issue><spage>2787</spage><epage>2795</epage><pages>2787-2795</pages><issn>0939-5555</issn><issn>1432-0584</issn><eissn>1432-0584</eissn><abstract>We evaluated RDW in a single-center series of 61 consecutive patients with primary and secondary MF at diagnosis and during treatment with ruxolitinib (RUX) and examined any possible prognostic impact. Elevated RDW values were present in all but 4 patients at diagnosis with a median RDW of 18.9%. RDW was higher in subjects with palpable splenomegaly (
p
= 0.02), higher ferritin, as well as among those cases who did not receive any cytoreduction before RUX (
p
= 0.04). Interestingly, higher RDW at diagnosis also correlated with a shorter time from MF diagnosis to RUX start (-4.1 months per one RDW unit;
p
= 0.03). We observed a modest increase (< 1%) in RDW during the first 6 months of RUX treatment. In a multivariable random-intercept model that considered all time points and contained the covariates time and RUX dose, we also observed a clear decrease in RDW with increasing hemoglobin (Hb) during RUX (slope: -0.4% per g/dL of Hb;
p
< 0.001). The median RDW at diagnosis of 18.9% was used as a cut-off to identify two subgroups of patients [Group 1: RDW 19.0-25.7%; Group 2: RDW 13.1-18.7%], showing a difference in mortality [Group 1 vs. 2: crude HR 2.88;
p
= 0.01]. Using continuous RDW at diagnosis, the crude HR was 1.21 per RDW unit (
p
= 0.002). In a Cox model adjusted for gender, age and Hb at diagnosis, the HR was 1.13 per RDW unit (
p
= 0.07). RDW may have prognostic significance at MF diagnosis and during RUX, helping in the rapid detection of patients with poor prognosis.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>38864904</pmid><doi>10.1007/s00277-024-05801-0</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0939-5555 |
| ispartof | Annals of hematology, 2024-08, Vol.103 (8), p.2787-2795 |
| issn | 0939-5555 1432-0584 1432-0584 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3085113491 |
| source | MEDLINE; SpringerNature Journals |
| subjects | Adult Aged Aged, 80 and over Automation Biopsy Bone marrow Cytokines Erythrocyte Indices Female Hematology Hemoglobin Humans Male Medical prognosis Medicine Medicine & Public Health Middle Aged Mortality Mutation Nitriles - therapeutic use Oncology Primary Myelofibrosis - blood Primary Myelofibrosis - drug therapy Primary Myelofibrosis - mortality Prognosis Pyrazoles - therapeutic use Pyrimidines - therapeutic use Spleen Stem cells |
| title | Red cell distribution width and prognosis in myelofibrosis patients treated with ruxolitinib |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T03%3A35%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Red%20cell%20distribution%20width%20and%20prognosis%20in%20myelofibrosis%20patients%20treated%20with%20ruxolitinib&rft.jtitle=Annals%20of%20hematology&rft.au=Cattaneo,%20Daniele&rft.date=2024-08-01&rft.volume=103&rft.issue=8&rft.spage=2787&rft.epage=2795&rft.pages=2787-2795&rft.issn=0939-5555&rft.eissn=1432-0584&rft_id=info:doi/10.1007/s00277-024-05801-0&rft_dat=%3Cproquest_cross%3E3085113491%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3085161289&rft_id=info:pmid/38864904&rfr_iscdi=true |